Literature DB >> 11505408

Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia: a North Central Cancer Treatment Group exploratory investigation.

A Jatoi1, C L Loprinzi, J A Sloan, G G Klee, H E Windschitl.   

Abstract

BACKGROUND: Anorexia is a noxious symptom, and over half of patients with advanced cancer experience it. Neuropeptide Y (NPY), leptin, and cholecystokinin 8 (CCK8) have been implicated.
METHODS: This exploratory study 1) compared circulating concentrations of NPY and leptin between anorectic cancer patients and historic controls and 2) explored whether NPY, leptin, or CCK8 may serve as correlates of anorexia severity. Cancer patients met predefined eligibility criteria: 1) weight loss > or = 2.3 kg over the preceding 2 months and/or a physician-estimated caloric intake of < 20 calories per kilogram of body weight per day and 2) patient acknowledgment that appetite or weight loss was an ongoing problem.
RESULTS: Seventy-three cancer patients were studied, and > 90% reported a > or = 50% decline in appetite from baseline in the preceding 2 months. NPY levels were lower than control values: mean +/- standard deviation, 466 pg/mL +/- 161 pg/mL versus 560 pg/mL +/- 151 pg/mL, respectively (P = 0.004). Because a few (but not all) earlier studies suggested an age-related decline in NPY levels, a subgroup analysis was performed and found no age-adjusted difference in NPY levels between groups. Similarly, leptin concentrations were not different between groups. Significant correlations were not observed between anorexia severity and NPY, leptin, or CCK8 levels.
CONCLUSIONS: There were no differences in leptin and CCK8 levels between anorectic cancer patients and historic controls. Circulating concentrations of NPY, leptin, and CCK8 did not correlate with anorexia severity. However, the current results suggest a need for further examination of NPY in cancer-associated anorexia. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11505408     DOI: 10.1002/1097-0142(20010801)92:3<629::aid-cncr1363>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

Review 1.  Pathophysiology and treatment options for cardiac anorexia.

Authors:  Marat Fudim; Gabriel Wagman; Rebecca Altschul; Evin Yucel; Michelle Bloom; Timothy J Vittorio
Journal:  Curr Heart Fail Rep       Date:  2011-06

2.  Systemic zinc redistribution and dyshomeostasis in cancer cachexia.

Authors:  Pontus M A Siren; Matti J Siren
Journal:  J Cachexia Sarcopenia Muscle       Date:  2010-10-26       Impact factor: 12.910

3.  Cancer induces cardiomyocyte remodeling and hypoinnervation in the left ventricle of the mouse heart.

Authors:  Christian Mühlfeld; Suman Kumar Das; Frank R Heinzel; Albrecht Schmidt; Heiner Post; Silvia Schauer; Tamara Papadakis; Wolfgang Kummer; Gerald Hoefler
Journal:  PLoS One       Date:  2011-05-26       Impact factor: 3.240

4.  A systematic review of the overlap of fluid biomarkers in delirium and advanced cancer-related syndromes.

Authors:  Ingrid Amgarth-Duff; Annmarie Hosie; Gideon Caplan; Meera Agar
Journal:  BMC Psychiatry       Date:  2020-04-22       Impact factor: 3.630

Review 5.  Pathophysiology of anorexia in the cancer cachexia syndrome.

Authors:  Chukwuemeka Charles Ezeoke; John E Morley
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-10-27       Impact factor: 12.910

Review 6.  Cachexia, a Systemic Disease beyond Muscle Atrophy.

Authors:  Elisabeth Wyart; Laure B Bindels; Erica Mina; Alessio Menga; Serena Stanga; Paolo E Porporato
Journal:  Int J Mol Sci       Date:  2020-11-14       Impact factor: 5.923

Review 7.  Understanding Cachexia in Head and Neck Cancer.

Authors:  Sivaramakrishnan Muthanandam; Jananni Muthu
Journal:  Asia Pac J Oncol Nurs       Date:  2021-08-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.